PT Pyridam Farma TbkISX:PYFA -0.98%67 Days Payable is 48.68 as of Mar. 2026, which is 40% above its 10-year median of 34.66. GuruFocus rates ISX:PYFA with a GF Score™ of 67/100 and a GF Value™ of Rp212.48 (Fairly Valued). The stock has 8 warning signs investors should review. Among 922 Drug Manufacturers companies, PT Pyridam Farma Tbk ranks worse than 79.5% on this metric.
The historical rank and industry rank for PT Pyridam Farma Tbk's Days Payable or its related term are showing as below:
ISX:PYFA'
s Days Payable Range Over the Past 10 Years
Min: 21.48 Med: 34.66 Max: 64.46
Current: 45.53
During the past 13 years, PT Pyridam Farma Tbk's highest Days Payable was 64.46. The lowest was 21.48. And the median was 34.66.
ISX:PYFA's Days Payable is ranked worse than 79.5% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.455
vs ISX:PYFA: 45.53
PT Pyridam Farma Tbk's Days Payable
increased
from Mar. 2025 (46.20) to Mar. 2026 (48.68).
It may suggest that PT Pyridam Farma Tbkdelayed paying its suppliers.
PT Pyridam Farma Tbk Days Payable Related Terms
PT Pyridam Farma Tbk Days Payable Historical Data
* Premium members only.
The historical data trend for PT Pyridam Farma Tbk's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PYFA vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's Days Payable distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PT Pyridam Farma Tbk's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a Days Payable of 48.68 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PT Pyridam Farma Tbk and its competitors. This is 40% above median its historical median of 34.66. Over the past decade, PT Pyridam Farma Tbk's Days Payable has ranged from 21.48 to 64.46. According to the industry distribution chart, PT Pyridam Farma Tbk ranks #733 out of 922 companies in the Drug Manufacturers industry, placing it in the top 79.5%.
Is PT Pyridam Farma Tbk's Days Payable too high?
PT Pyridam Farma Tbk's current Days Payable of 48.68 is 40% above median its 10-year median of 34.66. Over the past 10 years, this metric has ranged from a low of 21.48 to a high of 64.46. The Drug Manufacturers industry median Days Payable is 90.46. PT Pyridam Farma Tbk's value of 48.68 is 46.2% below this industry median. Based on the distribution chart, PT Pyridam Farma Tbk ranks #733 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Pyridam Farma Tbk has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Pyridam Farma Tbk ranks #733 out of 922 companies for Days Payable. This places PT Pyridam Farma Tbk in the lower half of its industry. The industry median Days Payable is 90.46. PT Pyridam Farma Tbk's value of 48.68 is 46.2% below this benchmark. Historically, PT Pyridam Farma Tbk's own Days Payable has ranged from 21.48 to 64.46 over the past decade. While the company's 10-year median is 34.66 vs. the industry median of 90.46, PT Pyridam Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.46, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Pyridam Farma Tbk's current Days Payable of 48.68 is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PT Pyridam Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Pyridam Farma Tbk's current Days Payable is 48.68, which is 40% above median its own 10-year median of 34.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Fairly Valued. The stock's GF Value™ is Rp212.48, compared to a current price of Rp202.00 — trading 4.9% below its estimated fair value. The current Days Payable is 48.68, which is 40% above median its 10-year median of 34.66 and 46.2% below the Drug Manufacturers industry median of 90.46. PT Pyridam Farma Tbk's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Days Payable is 48.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued.
The current stock price of Rp202.00 is trading 4.9% below its estimated GF Value™ of Rp212.48.
GuruFocus considers PT Pyridam Farma Tbk to be Fairly Valued.
Key valuation signals for ISX:PYFA:
Days Payable: 48.68 (40% above median its 10-year median of 34.66)
GF Value™: Rp212.48 vs. price of Rp202.00 (4.9% below fair value)
Industry Position: 46.2% below the Drug Manufacturers median (#733 of 922)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
67GF Score
Get the complete analysis for ISX:PYFA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
